Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.64 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581312 | 0.91 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1IMPDH2 | |
| SCHEMBL29936666 | 0.88 | ADORA3 (0.78) | ADORA3RNASELADORA2AADORA2BADORA1 | |
| SCHEMBL8622533 | 0.88 | ADORA3 (0.78) | ADORA3RNASELADORA2AADORA2BADORA1 | |
| SCHEMBL6663776 | 0.88 | ADORA3 (0.69) | ADORA3RNASELADORA2AADORA2BADORA1 | |
| SCHEMBL1898711 | 0.87 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| SCHEMBL1898718 | 0.87 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| SCHEMBL1469233 | 0.86 | RNASEL (0.56) | RNASELADORA1IMPDH2IMPDH1NT5E | |
| SCHEMBL1469227 | 0.86 | RNASEL (0.56) | RNASELADORA1IMPDH2IMPDH1NT5E | |
| SCHEMBL29936335 | 0.86 | ADORA3 (0.61) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| SCHEMBL9413293 | 0.86 | ADORA3 (0.61) | ADORA3ADORA2AADORA2BADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-3852814-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061397-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-3052479-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |